HomeMarkets Markets This Key Gene-Editing Test Is Dragging Down All CRISPR Stocks By news September 16, 2022 0 236 FacebookTwitterPinterestWhatsApp Intellia Therapeutics (NTLA) said early Friday it found a way to knock out the gene responsible for a rare and deadly swelling disorder — but NTLA …This post was originally published on this site Share FacebookTwitterPinterestWhatsApp Subscribe Login Notify of new follow-up comments new replies to my comments Please login to comment 0 Comments Inline Feedbacks View all comments Stay Connected156,331FansLike396,312FollowersFollow2,330SubscribersSubscribe Latest Articles Markets The Syrian Consequence: Russia’s Withdrawal Market News Trump wanted $90M for inauguration while cutting $190M from cancer research: lawmaker Biotech The First Sleep Apnea Drug Is Here Charts PSW’s Last Webinar of the Year & FED Meeting! Market News Trump was poised to inherit a strong economy. Then things got rocky and he added to the uncertainty Biotech Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps Markets The Syrian Consequence: Iran Goes “Defensive” Markets Stock market is more concentrated than ever, raising risks Markets Falling Friday – Stop the Week – We Want to Get Off! Market News Trump-backed funding bill fails as government shutdown looms Hot Items As China expands its cyber espionage and sabotage operations, how will the Trump administration respond? Markets Ukraine war: as 2025 approaches, Kyiv is left with few good options and allies in a Trump 2.0 world Market News As firms abandon VMware, Broadcom is laughing all the way to the bank Biotech Carfentanil is 100 times more potent than fentanyl, and it’s killing people Load more